GSK (NYSE:GSK) stock was up 3% in afternoon trading Tuesday in the wake of a ruling by a Delaware court on whether certain evidence should be allowed in an ongoing case over the safety of its recalled drug Zantac.

In a statement released Tuesday afternoon, GSK (GSK) said the Delaware Supreme Court has granted an interlocutory appeal that will review a decision made by a lower court that allowed the admission of certain plaintiff expert testimony regarding Zantac’s safety.

Plaintiffs in the case have argued that ranitidine can cause cancer. The drug was marketed for years by GSK (GSK) under the brand name Zantac and by various generic drugmakers.

GSK (GSK) said in its statement that “scientific consensus remains that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.”

“The Delaware litigation will progress in parallel with the Delaware Supreme Court review. Alongside review by the Delaware Supreme Court, the company will press additional defenses in the litigation, including failure to provide proof of use and proof of diagnosis requirements recently ordered by the court,” GSK added.

Earlier this month, GSK (GSK) announced that it plans to seek the dismissal of an upcoming Zantac-related lawsuit in Florida after a state court found that the expert testimony backing the plaintiff was unreliable. The company also prevailed in a Zantac lawsuit filed in Illinois.

First approved in 1983, Zantac was pulled from the U.S. market in 2020 after the FDA was notified that the drug led to the formation of unacceptably high levels of N-nitrosodimethylamine (NDMA), a potential carcinogen.